The latest price and purchasing channels of Ivonescimab injection in 2025

Ivonescimab injection (Ivonescimab) is the world's first new PD-1/VEGF bispecific immunotherapy drug independently developed by Akeso. It is called SMT112 in the licensed area of Summit Therapeutics. The drug has been approved by China's National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer (NSCLC), especially those who have progressed after EGFR·TKI therapy.

The first indication of ivocilimab has been approved in China, and currentlyAkeso is conducting 5 phase III clinical trials, including 2 global multicenter clinical trials (MRCTs) and 4 registration trials for anti-PD-1 therapies. In addition to these trials, Akeso is also exploring the application of ivocilimab in other cancers, currently covering 16 indications, including gastrointestinal cancer, hepatocellular carcinoma and colorectal cancer. Such extensive research aims to improve the scope of clinical application of this drug and bring treatment hope to more cancer patients.

The original drug of ivocilimab injection has been launched in China and has entered the scope of Class B medical insurance reimbursement, allowing patients to reduce their financial burden when receiving treatment. The common supply specification is 100 mg/10 ml, and each box may be sold for more than 2,000 yuan. This price level is relatively reasonable in the current anti-cancer drug market, especially considering its unique bispecific mechanism and efficacy against specific cancers.

Although evocilimab has been launched in the Chinese market and is covered by medical insurance, there are currently no other brands of evocilimab injection available for sale domestically or internationally. This means that market competition for this drug is still at a preliminary stage and may change in the future as more clinical data is released and other manufacturers participate.

Reference materials:https://www.akesobio.com/en/media/akeso-news/240908/